New Head of Research & Development at sanofi-aventis

Dr Marc CLUZEL appointed Senior Vice President, Science and Medical Affairs, to succeed Gérard LE FUR Paris - January 5, 2007 - As from January 1, 2007, Dr Marc CLUZEL is appointed Senior Vice President, Science and Medical Affairs. He succeeds Gérard LE FUR, who has been named Chief Executive Officer of sanofi-aventis. Marc CLUZEL, age 51, is a Medical Doctor, Pneumologist and holds a Ph.D. in Biochemistry. After a 6-year hospital medical activity, he worked as a Visiting Assistant Professor of Medicine, at the Johns Hopkins University from 1987 to 1990 and as a Research Associate at the London Guy’s Hospital, from 1990 to 1991. He joined Sanofi Recherche in 1991 within the Clinical Development department, and was appointed successively Senior Project Director in 1993, Vice President, Research Projects Management in 1996 and Vice President, International Development in 2001. Since 2005, he was Senior Vice President, International Development for sanofi-aventis. As from January 1, 2007, Dr. Sol RAJFER is appointed Senior Vice President, Deputy of the Senior Vice President Science and Medical Affairs. Sol RAJFER will maintain his responsibility as President of US Scientific and Medical Affairs for sanofi-aventis. Sol RAJFER, M.D., was Assistant Professor of Medicine at the University of Chicago, and held various positions at Merck Research Laboratories and Bristol-Myers Squibb. He joined Aventis Pharmaceuticals in 2000 as Senior Vice President and Global Head of Product Realization. He was appointed President of US Scientific and Medical Affairs, and Deputy Head of International Development at sanofi-aventis, in 2005. As from January 1, 2007, Dr. Jean-Philippe SANTONI is appointed Senior Vice President, International Development. He succeeds Marc CLUZEL, and will manage the Development activities on a worldwide basis. Jean-Philippe SANTONI, M.D., joined Synthélabo in 1990 as Cardiovascular Development Director and, in 2001, was appointed Vice President, International Clinical Operations, Sanofi-Synthélabo Research. Since 2004, he was Vice President, International Clinical Development for sanofi-aventis. As from January 1, 2007, Dr. Kazuji TAWARA, Vice President, Scientific Affairs Japan, will report directly to Marc CLUZEL, in line with the Group’s strategy to develop Research & Development activities in Japan. Kazuji TAWARA, MD, held various positions in the pharmaceutical industry and joined Sanofi-Synthelabo K.K. in 2003, as Vice President, Head of Research & Development in Japan. In 2004, he was appointed Deputy Head, Scientific Affairs in Japan, for sanofi-aventis and has been appointed Vice President, Scientific Affairs Japan, in 2005. About sanofi-aventis Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).